一种新的癌症药物显示,先接受过治疗的先进的膀胱癌病人有很强的结果,反应率达到31%,副作用是可以控制的。 A new cancer drug shows strong results in advanced bladder cancer patients who’ve had prior treatments, with a 31% response rate and manageable side effects.

在肿瘤学Annals的《肿瘤学年鉴》上公布的第二阶段试验显示,TROP2目标抗体药物共产物Sactuuzumab tirumotecan(Sac-TMT)是TROP2-目标抗体药物目标共合体,对有前科治疗的先进的泌尿皮癌患者有31%的确认反应率,包括50%的二线治疗,还有71%的疾病控制率。 A phase II trial published in Annals of Oncology shows sacituzumab tirumotecan (sac-TMT), a TROP2-targeted antibody-drug conjugate, has a 31% confirmed response rate in advanced urothelial carcinoma patients with prior treatments, including 50% in second-line use, and a 71% disease control rate. 由于中位无进展的存活率为5.5个月,53%的应答者保持12个月的反应,该药物显示出可控制的安全状况,没有致命的治疗事件。 With a median progression-free survival of 5.5 months and 53% of responders maintaining response at 12 months, the drug demonstrated a manageable safety profile, with no fatal treatment-related events. Sichuan Kelun-Biotech开发的sac-TMT使用新型连线器提供托波异构体酶I抑制剂,给选择有限的患者带来了希望。 Developed by Sichuan Kelun-Biotech, sac-TMT uses a novel linker to deliver a topoisomerase I inhibitor, showing promise for patients with limited options. 中国已经批准对某些癌症进行治疗,并正在对此进行审查,以了解更多迹象。 It is already approved in China for certain cancers and is under review for additional indications.